Leiden, The Netherlands, July 20, 2007. Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) announced today its results for the first half year (HY1) of 2007 ended June 30, 2007. The financial results are in line with expectations communicated earlier this year, while important progress has been realized in the development of Pharming’s lead product Rhucin®.